Effect of atypical antipsychotics on fetal growth: Is the placenta involved?

Journal of Pregnancy

Volumn 2012, Issue , 2012, Pages

  Raha, Sandeep ^a   Taylor, Valerie H ^b   Holloway, Alison C ^a  

^a MCMASTER UNIVERSITY   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

NEUROLEPTIC AGENT;

DRUG EFFECT; FEMALE; FETUS DEVELOPMENT; HUMAN; MENTAL DISEASE; METABOLISM; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PLACENTA; PREGNANCY; PREGNANCY COMPLICATION; REVIEW;

ANTIPSYCHOTIC AGENTS; FEMALE; FETAL DEVELOPMENT; HUMANS; MENTAL DISORDERS; OXIDATIVE STRESS; PLACENTA; PREGNANCY; PREGNANCY COMPLICATIONS;

EID: 84866258856     PISSN: 20902727     EISSN: 20902735     Source Type: Journal    
DOI: 10.1155/2012/315203     Document Type: Review

References (116)

1. Bebbington P., Dunn G., Jenkins R., Lewis G., Brugha T., Farrell M., Meltzer H., The influence of age and sex on the prevalence of depressive conditions: report from the National Survey of Psychiatric Morbidity. International Review of Psychiatry 2003 15 1-2 74 83 2-s2.0-0037301065 10.1080/0954026021000045976 (Pubitemid 36363528)
2. Zender R., Olshansky E., Women's mental health: depression and anxiety. Nursing Clinics of North America 2009 44 3 355 364 2-s2.0-68349091586 10.1016/j.cnur.2009.06.002
3. Akdeniz F., Female-specific health problems in mental patients. Current Opinion in Psychiatry 2010 23 4 378 382 2-s2.0-77953543838 10.1097/YCO. 0b013e32833ae437
4. Figueira M. L., Ouakinin S., Gender-related endocrinological dysfunction and mental disorders. Current Opinion in Psychiatry 2010 23 4 369 372 2-s2.0-77953519651 10.1097/YCO.0b013e3283399b86
5. Soares C. N., DSM-V and reproductive-related psychiatric disorders: a closer look at windows of vulnerability. Archives of Women's Mental Health 2010 13 1 15 16 2-s2.0-76449105459 10.1007/s00737-009-0116-z
6. Levey L., Ragan K., Hower-Hartley A., Newport D. J., Stowe Z. N., Psychiatric disorders in pregnancy. Neurologic Clinics 2004 22 4 863 893 2-s2.0-4944250533 10.1016/j.ncl.2004.07.003 (Pubitemid 39330305)
7. Menon S. J., Psychotropic medication during pregnancy and lactation. Archives of Gynecology and Obstetrics 2008 277 1 1 13 2-s2.0-36348946863 10.1007/s00404-007-0433-2 (Pubitemid 350160081)
8. Solari H., Dickson K. E., Miller L., Understanding and treating women with schizophrenia during pregnancy and postpartum. Canadian Journal of Clinical Pharmacology 2009 16 1 e23 e32 2-s2.0-61949186370
9. ACOG, Use of psychiatric medications during pregnancy and lactation. ACOG Practice Bulletin 2008 111 1001 1020
10. Weiss E., Hummer M., Koller D., Ulmer H., Fleischhacker W. W., Off-label use of antipsychotic drugs. Journal of Clinical Psychopharmacology 2000 20 6 695 698 2-s2.0-0033711757 10.1097/00004714-200012000-00018
11. Philip N. S., Carpenter L. L., Tyrka A. R., Price L. H., Augmentation of antidepressants with atypical antipsychotics: a review of the current literature. Journal of Psychiatric Practice 2008 14 1 34 44 2-s2.0-38549181516 10.1097/01.pra.0000308493.93003.92 (Pubitemid 351158846)
12. Boonstra G., Grobbee D. E., Hak E., Kahn R. S., Burger H., Initiation of antipsychotic treatment by general practitioners. A case-control study. Journal of Evaluation in Clinical Practice 2011 17 1 12 17 2-s2.0-78751677888 10.1111/j.1365-2753.2009.01352.x
13. Meltzer H. Y., Matsubara S., Lee J. C., Classification of typical and atypical antipsychotic drugs on the basis of dopamine D-1, D-2 and serotonin2 pK(i) values. Journal of Pharmacology and Experimental Therapeutics 1989 251 1 238 246 2-s2.0-0024466603
14. McKenna K., Einarson A., Levinson A., Gideon K., Significant changes in antipsychotic drug use during pregnancy. Veterinary and Human Toxicology 2004 46 1 44 46 2-s2.0-0347634359 (Pubitemid 38095889)
15. Trixler M., Gáti Á., Fekete S., Tényi T., Use of antipsychotics in the management of schizophrenia during pregnancy. Drugs 2005 65 9 1193 1206 2-s2.0-22744454543 10.2165/00003495-200565090-00002 (Pubitemid 41032046)
16. Oyebode F., Rastogi A., Berrisford G., Coccia F., Psychotropics in pregnancy: safety and other considerations. Pharmacology and Therapeutics 2012 135 1 71 77 10.1016/j.pharmthera.2012.03.008
17. Seeman P., Lee T., Chau-Wong M., Wong K., Antipsychotic drug doses and neuroleptic/dopamine receptors. Nature 1976 261 5562 717 719 2-s2.0-0017068246
18. Kurosawa S., Hashimoto E., Ukai W., Toki S., Saito S., Saito T., Olanzapine potentiates neuronal survival and neural stem cell differentiation: regulation of endoplasmic reticulum stress response proteins. Journal of Neural Transmission 2007 114 9 1121 1128 2-s2.0-34548165477 10.1007/s00702-007-0747-z (Pubitemid 47313177)
19. Beauvais G., Atwell K., Jayanthi S., Ladenheim B., Cadet J. L., Involvement of dopamine receptors in binge methamphetamine-induced activation of endoplasmic reticulum and mitochondrial stress pathways. PLoS ONE 2011 6 12 e28946
20. Bubser M., Backstrom J. R., Sanders-Bush E., Roth B. L., Deutch A. Y., Distribution of serotonin 5-HT(2A) receptors in afferents of the rat striatum. Synapse 2001 39 4 297 304 (Pubitemid 32128651)
21. Jafari S., Fernandez-Enright F., Huang X. F., Structural contributions of antipsychotic drugs to their therapeutic profiles and metabolic side effects. Journal of Neurochemistry 2011 120 3 371 384
22. McCauley-Elsom K., Gurvich C., Elsom S. J., Kulkarni J., Antipsychotics in pregnancy. Journal of Psychiatric and Mental Health Nursing 2010 17 2 97 104 2-s2.0-77949292453 10.1111/j.1365-2850.2009.01481.x
23. McKenna K., Koren G., Tetelbaum M., Wilton L., Shakir S., Diav-Citrin O., Levinson A., Zipursky R. B., Einarson A., Pregnancy outcome of women using atypical antipsychotic drugs: a prospective comparative study. Journal of Clinical Psychiatry 2005 66 4 444 449 2-s2.0-17844394421 (Pubitemid 40593572)
24. Newham J. J., Thomas S. H., MacRitchie K., McElhatton P. R., McAllister-Williams R. H., Birth weight of infants after maternal exposure to typical and atypical antipsychotics: prospective comparison study. British Journal of Psychiatry 2008 192 5 333 337 2-s2.0-43749107296 10.1192/bjp.bp.107. 041541 (Pubitemid 351692376)
25. Peindl K. S., Masand P., Mannelli P., Narasimhan M., Patkar A., Polypharmacy in pregnant women with major psychiatric illness: a pilot study. Journal of Psychiatric Practice 2007 13 6 385 392 2-s2.0-36349011343 10.1097/01.pra.0000300124.83945.b8 (Pubitemid 350158944)
26. Boyda H. N., Tse L., Procyshyn R. M., Honer W. G., Barr A. M., Preclinical models of antipsychotic drug-induced metabolic side effects. Trends in Pharmacological Sciences 2010 31 10 484 497 2-s2.0-77956898286 10.1016/j.tips.2010.07.002
27. Coccurello R., Moles A., Potential mechanisms of atypical antipsychotic-induced metabolic derangement: clues for understanding obesity and novel drug design. Pharmacology and Therapeutics 2010 127 3 210 251 2-s2.0-77954218128 10.1016/j.pharmthera.2010.04.008
28. Newport D. J., Calamaras M. R., DeVane C. L., Donovan J., Beach A. J., Winn S., Knight B. T., Gibson B. B., Viguera A. C., Owens M. J., Nemeroff C. B., Stowe Z. N., Atypical antipsychotic administration during late pregnancy: placental passage and obstetrical outcomes. American Journal of Psychiatry 2007 164 8 1214 1220 2-s2.0-34548100318 10.1176/appi.ajp.2007.06111886 (Pubitemid 47292410)
29. Babu G. N., Desai G., Tippeswamy H., Chandra P. S., Birth weight and use of olanzapine in pregnancy: a prospective comparative study. Journal of Clinical Psychopharmacology 2010 30 3 331 332 2-s2.0-77952349372 10.1097/JCP. 0b013e3181db8734
30. Taylor P. D., Poston L., Developmental programming of obesity in mammals. Experimental Physiology 2007 92 2 287 298 2-s2.0-33847716354 10.1113/expphysiol.2005.032854 (Pubitemid 46376323)
31. Simmons R., Perinatal programming of obesity. Seminars in Perinatology 2008 32 5 371 374 2-s2.0-52949112689 10.1053/j.semperi.2008.08.004
32. Oken E., Maternal and child obesity: the causal link. Obstetrics and Gynecology Clinics of North America 2009 36 2 361 377 2-s2.0-66149172037 10.1016/j.ogc.2009.03.007
33. Reynolds G. P., Kirk S. L., Metabolic side effects of antipsychotic drug treatmentpharmacological mechanisms. Pharmacology and Therapeutics 2010 125 1 169 179 2-s2.0-72149090641 10.1016/j.pharmthera.2009.10.010
34. Seeman M. V., Secondary effects of antipsychotics: women at greater risk than men. Schizophrenia Bulletin 2009 35 5 937 948 2-s2.0-69249118537 10.1093/schbul/sbn023
35. Rummel-Kluge C., Komossa K., Schwarz S., Hunger H., Schmid F., Lobos C. A., Kissling W., Davis J. M., Leucht S., Head-to-head comparisons of metabolic side effects of second generation antipsychotics in the treatment of schizophrenia: a systematic review and meta-analysis. Schizophrenia Research 2010 123 2-3 225 233 2-s2.0-77957923642 10.1016/j.schres.2010.07.012
36. Bergman R. N., Ader M., Atypical antipsychotics and glucose homeostasis. Journal of Clinical Psychiatry 2005 66 4 504 514 2-s2.0-17844403749 (Pubitemid 40593580)
37. Chaggar P. S., Shaw S. M., Williams S. G., Effect of antipsychotic medications on glucose and lipid levels. Journal of Clinical Pharmacology 2011 51 5 631 638 2-s2.0-79955529007 10.1177/0091270010368678
38. Cooper G. D., Pickavance L. C., Wilding J. P. H., Halford J. C. G., Goudie A. J., A parametric analysis of olanzapine-induced weight gain in female rats. Psychopharmacology 2005 181 1 80 89 2-s2.0-26644458378 10.1007/s00213-005-2224-4 (Pubitemid 41440918)
39. Kalinichev M., Rourke C., Daniels A. J., Grizzle M. K., Britt C. S., Ignar D. M., Jones D. N. C., Characterisation of olanzapine-induced weight gain and effect of aripiprazole vs olanzapine on body weight and prolactin secretion in female rats. Psychopharmacology 2005 182 2 220 231 2-s2.0-26844446471 10.1007/s00213-005-0081-9 (Pubitemid 41464615)
40. Nielsen J., Skadhede S., Correll C. U., Antipsychotics associated with the development of type 2 diabetes in antipsychotic-naïve schizophrenia patients. Neuropsychopharmacology 2010 35 9 1997 2004 2-s2.0-77954762965 10.1038/npp.2010.78
41. Reis M., Källén B., Maternal use of antipsychotics in early pregnancy and delivery outcome. Journal of Clinical Psychopharmacology 2008 28 3 279 288 2-s2.0-51449100218 10.1097/JCP.0b013e318172b8d5
42. Holt R. I. G., Peveler R. C., Byrne C. D., Schizophrenia, the metabolic syndrome and diabetes. Diabetic Medicine 2004 21 6 515 523 2-s2.0-1842818702 10.1111/j.1464-5491.2004.01199.x (Pubitemid 38746268)
43. Ehrenberg H. M., Mercer B. M., Catalano P. M., The influence of obesity and diabetes on the prevalence of macrosomia. American Journal of Obstetrics and Gynecology 2004 191 3 964 968 2-s2.0-4644278595 10.1016/j.ajog.2004.05.052 (Pubitemid 39298142)
44. Metzger B. E., Lowe L. P., Dyer A. R., Hyperglycemia and adverse pregnancy outcomes. The New England Journal of Medicine 2008 358 19 1991 2002 (Pubitemid 351656454)
45. Miyakoshi K., Tanaka M., Saisho Y., Shimada A., Minegishi K., Kim S. H., Asai S., Itoh H., Yoshimura Y., Pancreatic β -cell function and fetal growth in gestational impaired glucose tolerance. Acta Obstetricia et Gynecologica Scandinavica 2010 89 6 769 775 2-s2.0-77952915343 10.3109/00016349.2010.487091
46. Donma M. M., Macrosomia, top of the iceberg: the charm of underlying factors. Pediatrics International 2011 53 1 78 84 2-s2.0-79951986445 10.1111/j.1442-200X.2010.03198.x
47. Davoodi N., Kalinichev M., Korneev S. A., Clifton P. G., Hyperphagia and increased meal size are responsible for weight gain in rats treated sub-chronically with olanzapine. Psychopharmacology 2009 203 4 693 702 2-s2.0-63449100443 10.1007/s00213-008-1415-1
48. Thornton-Jones Z., Neill J. C., Reynolds R., The atypical antipsychotic olanzapine enhances ingestive behaviour in the rat: a preliminary study. Journal of Psychopharmacology 2002 16 1 35 37 2-s2.0-0036205425 (Pubitemid 34273071)
49. Fell M. J., Marshall K. M., Williams J., Neill J. C., Effects of the atypical antipsychotic olanzapine on reproductive function and weight gain in female rats. Journal of Psychopharmacology 2004 18 2 149 155 2-s2.0-3242740983 10.1177/0269881104042613 (Pubitemid 38954901)
50. Minet-Ringuet J., Even P. C., Lacroix M., Tomé D., de Beaurepaire R., A model for antipsychotic-induced obesity in the male rat. Psychopharmacology 2006 187 4 447 454 2-s2.0-33746912797 10.1007/s00213-006- 0433-0 (Pubitemid 44200516)
51. Vestri H. S., Maianu L., Moellering D. R., Garvey W. T., Atypical antipsychotic drugs directly impair insulin action in adipocytes: effects on glucose transport, lipogenesis, and antilipolysis. Neuropsychopharmacology 2007 32 4 765 772 2-s2.0-33947274677 10.1038/sj.npp.1301142 (Pubitemid 46426168)
52. Yang L. H., Chen T. M., Yu S. T., Chen Y. H., Olanzapine induces SREBP-1-related adipogenesis in 3T3-L1 cells. Pharmacological Research 2007 56 3 202 208 2-s2.0-34548208771 10.1016/j.phrs.2007.05.007 (Pubitemid 47321203)
53. Tan W., Fan H., Yu P. H., Induction of subcutaneous adipose proliferation by olanzapine in rodents. Progress in Neuro-Psychopharmacology and Biological Psychiatry 2010 34 6 1098 1103 2-s2.0-77955056145 10.1016/j.pnpbp.2010.06.002
54. Chintoh A. F., Mann S. W., Lam L., Lam C., Cohn T. A., Fletcher P. J., Nobrega J. N., Giacca A., Remington G., Insulin resistance and decreased glucose-stimulated insulin secretion after acute olanzapine administration. Journal of Clinical Psychopharmacology 2008 28 5 494 499 2-s2.0-58149109332 10.1097/JCP.0b013e318184b4c5
55. Chintoh A. F., Mann S. W., Lam L., Giacca A., Fletcher P., Nobrega J., Remington G., Insulin resistance and secretion in vivo: effects of different antipsychotics in an animal model. Schizophrenia Research 2009 108 13 127 133 2-s2.0-60249097928 10.1016/j.schres.2008.12.012
56. Fatemi S. H., Olanzapine increases glucogenesis by multiple pathways in brain and muscle. Molecular Psychiatry 2006 11 6 524 525 2-s2.0-33745726798 10.1038/sj.mp.4001821
57. Best L., Yates A. P., Reynolds G. P., Actions of antipsychotic drugs on pancreatic β -cell function: contrasting effects of clozapine and haloperidol. Journal of Psychopharmacology 2005 19 6 597 601 2-s2.0-27644536615 10.1177/0269881105056641 (Pubitemid 41578820)
58. Melkersson K., Jansson E., Effects of the atypical antipsychotic clozapine on insulin release in vitro. Neuroendocrinology Letters 2007 28 6 854 860 2-s2.0-37849041094
59. Melkersson K., Jansson E., The atypical antipsychotics quetiapine, risperidone and ziprasidone do not increase insulin release in vitro. Neuroendocrinology Letters 2005 26 3 205 208 2-s2.0-22144469147 (Pubitemid 40975097)
60. Smith S. A., Hulsey T., Goodnight W., Effects of obesity on pregnancy. Journal of Obstetric, Gynecologic, and Neonatal Nursing 2008 37 2 176 184 2-s2.0-40949140225 10.1111/j.1552-6909.2008.00222.x
61. Rowlands I., Graves N., de Jersey S., McIntyre H. D., Callaway L., Obesity in pregnancy: outcomes and economics. Seminars in Fetal and Neonatal Medicine 2010 15 2 94 99 2-s2.0-77349115177 10.1016/j.siny.2009.09.003
62. McCurdy C. E., Bishop J. M., Williams S. M., Grayson B. E., Smith M. S., Friedman J. E., Grove K. L., Maternal high-fat diet triggers lipotoxicity in the fetal livers of nonhuman primates. Journal of Clinical Investigation 2009 119 2 323 335 2-s2.0-61749094289 10.1172/JCI32661
63. Kristensen J., Vestergaard M., Wisborg K., Kesmodel U., Secher N. J., Pre-pregnancy weight and the risk of stillbirth and neonatal death. BJOG: An International Journal of Obstetrics and Gynaecology 2005 112 4 403 408 2-s2.0-17144418097 10.1111/j.1471-0528.2005.00437.x (Pubitemid 40516551)
64. Arendas K., Qiu Q., Gruslin A., Obesity in pregnancy: pre-conceptional to postpartum consequences. Journal of Obstetrics and Gynaecology Canada 2008 30 6 477 488 2-s2.0-53449086445
65. Satpathy H. K., Fleming A., Frey D., Barsoom M., Satpathy C., Fossen K., Maternal obesity and pregnancy. Postgraduate Medicine 2008 120 3 1 9 2-s2.0-56149114119 10.3810/pgm.2008.09.1920
66. Yogev Y., Visser G. H. A., Obesity, gestational diabetes and pregnancy outcome. Seminars in Fetal and Neonatal Medicine 2009 14 2 77 84 2-s2.0-60849099905 10.1016/j.siny.2008.09.002
67. Howie G. J., Sloboda D. M., Kamal T., Vickers M. H., Maternal nutritional history predicts obesity in adult offspring independent of postnatal diet. Journal of Physiology 2009 587 4 905 915 2-s2.0-60349113479 10.1113/jphysiol. 2008.163477
68. Sloboda D. M., Beedle A. S., Cupido C. L., Gluckman P. D., Vickers M. H., Impaired perinatal growth and longevity: a life history perspective. Current Gerontology and Geriatrics Research 2009 2009 6 608740 10.1155/2009/608740
69. Hayes E. K., Lechowicz A., Petrik J. J., Adverse fetal and neonatal outcomes associated with a life-long high fat diet: role of altered development of the placental vasculature. PLoS ONE 2012 7 3 e33370
70. Lopez-Yarto M., Ruiz-Mirazo E., Holloway A. C., Taylor V. H., McDonald S. D., Do psychiatric medications, especially antidepressants, adversely impact maternal metabolic outcomes? Journal of Affective Disorders. In press 10.1016/j.jad.2012.01.043
71. Schenker S., Yang Y., Mattiuz E., Tatum D., Lee M., Olanzapine transfer by human placenta. Clinical and Experimental Pharmacology and Physiology 1999 26 9 691 697 2-s2.0-0032871184 10.1046/j.1440-1681.1999.03111.x (Pubitemid 29437240)
72. Ain R., Konno T., Canham L. N., Soares M. J., Phenotypic analysis of the rat placenta. Methods in Molecular Medicine 2006 121 295 313 2-s2.0-33644648927
73. Freedman R., Schizophrenia. The New England Journal of Medicine 2003 349 18 1738 1749 2-s2.0-0142244688 10.1056/NEJMra035458 (Pubitemid 37315012)
74. Viau M., Lafond J., Vaillancourt C., Expression of placental serotonin transporter and 5-HT2A receptor in normal and gestational diabetes mellitus pregnancies. Reproductive Biomedicine Online 2009 19 2 207 215 2-s2.0-69249156542 10.1016/S1472-6483(10)60074-0
75. Guillet-Deniau I., Burnol A. F., Girard J., Identification and localization of a skeletal muscle secrotonin 5-HT(2A) receptor coupled to the Jak/STAT pathway. The Journal of Biological Chemistry 1997 272 23 14825 14829 2-s2.0-0030902977 10.1074/jbc.272.23.14825 (Pubitemid 27251752)
76. Banes A. K. L., Shaw S. M., Tawfik A., Patel B. P., Ogbi S., Fulton D., Marrero M. B., Activation of the JAK/STAT pathway in vascular smooth muscle by serotonin. American Journal of Physiology 2005 288 4 C805 C812 2-s2.0-15444366204 10.1152/ajpcell.00385.2004 (Pubitemid 40395058)
77. Klempan T., Hudon-Thibeault A. A., Oufkir T., Vaillancourt C., Sanderson J. T., Stimulation of serotonergic 5-HT2A receptor signaling increases placental aromatase (CYP19) activity and expression in BeWo and JEG-3 human choriocarcinoma cells. Placenta 2011 32 9 651 656 2-s2.0-79959335186 10.1016/j.placenta.2011.06.003
78. Gambino Y. P., Maymo J. L., Perez Perez A., Calvo J. C., Sanchez-Margalet V., Varone C. L., Elsevier Trophoblast Research Award lecture: molecular mechanisms underlying estrogen functions in trophoblastic cellsfocus on leptin expression. Placenta 2012 33 S63 S70 10.1016/j.placenta.2011.12.001
79. Forhead A. J., Lamb C. A., Franko K. L., O'connor D. M., Wooding F. B. P., Cripps R. L., Ozanne S., Blache D., Shen Q. W., Du M., Fowden A. L., Role of leptin in the regulation of growth and carbohydrate metabolism in the ovine fetus during late gestation. Journal of Physiology 2008 586 9 2393 2403 2-s2.0-42949157703 10.1113/jphysiol.2007.149237 (Pubitemid 351619187)
80. Kirwin S. M., Bhandari V., Dimatteo D., Barone C., Johnson L., Paul S., Spitzer A. R., Chander A., Hassink S. G., Funanage V. L., Leptin enhances lung maturity in the fetal rat. Pediatric Research 2006 60 2 200 204 2-s2.0-33748044664 10.1203/01.pdr.0000227478.29271.52 (Pubitemid 44297593)
81. Mise H., Yura S., Itoh H., Nuamah M. A., Takemura M., Sagawa N., Fujii S., The relationship between maternal plasma leptin levels and fetal growth restriction. Endocrine Journal 2007 54 6 945 951 2-s2.0-40449140344 10.1507/endocrj.K06-225 (Pubitemid 351346778)
82. Duffield J. A., Vuocolo T., Tellam R., Yuen B. S., Muhlhausler B. S., McMillen I. C., Placental restriction of fetal growth decreases IGF1 and leptin mRNA expression in the perirenal adipose tissue of late gestation fetal sheep. American Journal of Physiology 2008 294 5 R1413 R1419 2-s2.0-45549108351 10.1152/ajpregu.00787.2007
83. Petit A., Vaillancourt C., Bellabarba D., Lehoux J. G., Gallo-Payet N., Belisle S., Presence of D2-dopamine receptors in human term placenta. Journal of Receptor Research 1990 10 3-4 205 215 2-s2.0-0025197650 (Pubitemid 20351123)
84. Vaillancourt C., Petit A., Gallo-Payet N., Bellabarba D., Lehoux J. G., Belisle S., Labelling of D2-dopaminergic and 5-HT2-serotonergic binding sites in human trophoblastic cells using [3H]-spiperone. Journal of Receptor Research 1994 14 1 11 22 2-s2.0-0028182045 (Pubitemid 24035477)
85. Hu D., Cross J. C., Development and function of trophoblast giant cells in the rodent placenta. International Journal of Developmental Biology 2010 54 2-3 341 354 2-s2.0-77950363751 10.1387/ijdb.082768dh
86. Cross J. C., Moffett A., Loke C., McLaren A., Trophoblast cell fate specification. Biology and Pathology of Trophoblast 2006 Cambridge, UK Cambridge University Press 3 14
87. Vaillancourt C., Petit A., Bélisle S., Expression of human placental D2-dopamine receptor during normal and abnormal pregnancies. Placenta 1998 19 1 73 80 2-s2.0-0031914208 10.1016/S0143-4004(98)90101-1 (Pubitemid 28112064)
88. Vaillancourt C., Petit A., Bélisle S., Interaction of D2-dopamine receptor with two pertussis toxin sensitive G proteins in human placenta. Life Sciences 1997 60 16 1365 1375 2-s2.0-0030611770 10.1016/S0024-3205(97)00082-9 (Pubitemid 27191931)
89. Govindaiah G., Wang T., Gillette M. U., Crandall S. R., Cox C. L., Regulation of inhibitory synapses by presynaptic D4 dopamine receptors in thalamus. Journal of Neurophysiology 2010 104 5 2757 2765 2-s2.0-78049526018 10.1152/jn.00361.2010
90. Matsumoto M., Hidaka K., Tada S., Tasaki Y., Yamaguchi T., Full-length cDNA cloning and distribution of human dopamine D4 receptor. Molecular Brain Research 1995 29 1 157 162 2-s2.0-0028916893 10.1016/0169-328X(94)00245-A
91. Freemark M., Kirk K., Pihoker C., Robertson M. C., Shiu R. P. C., Driscoll P., Pregnancy lactogens in the rat conceptus and fetus: circulating levels, distribution of binding, and expression of receptor messenger ribonucleic acid. Endocrinology 1993 133 4 1830 1842 2-s2.0-0027482486 10.1210/en.133.4.1830 (Pubitemid 23295216)
92. Wang H., Xu H., Dyck L. E., Li X. M., Olanzapine and quetiapine protect PC12 cells from β -amyloid peptide(2535)-induced oxidative stress and the ensuing apoptosis. Journal of Neuroscience Research 2005 81 4 572 580 2-s2.0-24744433317 10.1002/jnr.20570 (Pubitemid 41297394)
93. Magliaro B. C., Saldanha C. J., Clozapine protects PC-12 cells from death due to oxidative stress induced by hydrogen peroxide via a cell-type specific mechanism involving inhibition of extracellular signal-regulated kinase phosphorylation. Brain Research 2009 1283 14 24 2-s2.0-67651119865 10.1016/j.brainres.2009.05.063
94. Park S. W., Lee C. H., Lee J. G., Kim L. W., Shin B. S., Lee B. J., Kim Y. H., Protective effects of atypical antipsychotic drugs against MPP(+)-induced oxidative stress in PC12 cells. Neuroscience Research 2011 69 4 283 290 2-s2.0-79951958579 10.1016/j.neures.2011.01.004
95. Baig M. R., Navaira E., Escamilla M. A., Raventos H., Walss-Bass C., Clozapine treatment causes oxidation of proteins involved in energy metabolism in lymphoblastoid cells: a possible mechanism for antipsychotic-induced metabolic alterations. Journal of Psychiatric Practice 2010 16 5 325 333 2-s2.0-77957580499 10.1097/01.pra.0000388627.36781.6a
96. Zhang X. Y., Tan Y. L., Cao L. Y., Wu G. Y., Xu Q., Shen Y., Zhou D. F., Antioxidant enzymes and lipid peroxidation in different forms of schizophrenia treated with typical and atypical antipsychotics. Schizophrenia Research 2006 81 2-3 291 300 2-s2.0-30844435490 10.1016/j.schres.2005.10.011 (Pubitemid 43107705)
97. Martins M. R., Petronilho F. C., Gomes K. M., Dal-Pizzol F., Streck E. L., Quevedo J., Antipsychotic-induced oxidative stress in rat brain. Neurotoxicity Research 2008 13 1 63 69 2-s2.0-44649199519 10.1007/BF03033368
98. Raha S., Myint A. T., Johnstone L., Robinson B. H., Control of oxygen free radical formation from mitochondrial complex I: roles for protein kinase A and pyruvate dehydrogenase kinase. Free Radical Biology and Medicine 2002 32 5 421 430 2-s2.0-0036489190 10.1016/S0891-5849(01)00816-4 (Pubitemid 34178352)
99. Raha S., McEachern G. E., Myint A. T., Robinson B. H., Superoxides from mitochondrial complex III: the role of manganese superoxide dismutase. Free Radical Biology and Medicine 2000 29 2 170 180 2-s2.0-0034661024 10.1016/S0891-5849(00)00338-5
100. Fehsel K., Loeffler S., Krieger K., Henning U., Agelink M., Kolb-Bachofen V., Klimke A., Clozapine induces oxidative stress and proapoptotic gene expression in neutrophils of schizophrenic patients. Journal of Clinical Psychopharmacology 2005 25 5 419 426 2-s2.0-25444451402 10.1097/01.jcp. 0000177668.42640.fe (Pubitemid 41368363)
101. Raha S., Robinson B. H., Mitochondria, oxygen free radicals, disease and ageing. Trends in Biochemical Sciences 2000 25 10 502 508 2-s2.0-0034306267 10.1016/S0968-0004(00)01674-1
102. Ji B., La Y., Gao L., Zhu H., Tian N., Zhang M., Yang Y., Zhao X., Tang R., Ma G., Zhou J., Meng J., Ma J., Zhang Z., Li H., Feng G., Wang Y., He L., Wan C., A comparative proteomics analysis of rat mitochondria from the cerebral cortex and hippocampus in response to antipsychotic medications. Journal of Proteome Research 2009 8 7 3633 3641 2-s2.0-67650376532 10.1021/pr800876z
103. Raha S., Robinson B. H., Metabolic actions of free radicals: walking the tightrope. Heart and Metabolism 2003 19 4 10
104. Burkhardt C., Kelly J. P., Lim Y. H., Filley C. M., Parker W. D. Jr., Neuroleptic medications inhibit complex I of the electron transport chain. Annals of Neurology 1993 33 5 512 517 2-s2.0-0027177218 (Pubitemid 23143036)
105. Jackson-Lewis V., Przedborski S., Neuroleptic medications inhibit complex I of the electron transport chain. Annals of Neurology 1994 35 2 244 245 2-s2.0-0028045737 (Pubitemid 24050165)
106. Balijepalli S., Kenchappa R. S., Boyd M. R., Ravindranath V., Protein thiol oxidation by haloperidol results in inhibition of mitochondrial complex I in brain regions: comparison with atypical antipsychotics. Neurochemistry International 2001 38 5 425 435 2-s2.0-0035108147 10.1016/S0197-0186(00)00108-X (Pubitemid 32166900)
107. Barrientos A., Moraes C. T., Simultaneous transfer of mitochondrial DNA and single chromosomes in somatic cells: a novel approach for the study of defects in nuclear-mitochondrial communication. Human Molecular Genetics 1998 7 11 1801 1808 2-s2.0-0031718061 10.1093/hmg/7.11.1801 (Pubitemid 28464156)
108. Hroudova J., Fisar Z., Activities of respiratory chain complexes and citrate synthase influenced by pharmacologically different antidepressants and mood stabilizers. Neuroendocrinology Letters 2010 31 3 336 342 2-s2.0-77955444419
109. Rasbach K. A., Funk J. A., Jayavelu T., Green P. T., Schnellmann R. G., 5-Hydroxytryptamine receptor stimulation of mitochondrial biogenesis. Journal of Pharmacology and Experimental Therapeutics 2010 332 2 632 639 2-s2.0-76749130118 10.1124/jpet.109.159947
110. Casanueva E., Viteri F. E., Iron and oxidative stress in pregnancy. Journal of Nutrition 2003 133 5, supplement 2 1700S 1708S 2-s2.0-0037547073 (Pubitemid 36548678)
111. Gundogan F., Elwood G., Mark P., Feijoo A., Longato L., Tong M., De La Monte S. M., Ethanol-induced oxidative stress and mitochondrial dysfunction in rat placenta: relevance to pregnancy loss. Alcoholism: Clinical and Experimental Research 2010 34 3 415 423 2-s2.0-77749261106 10.1111/j.1530-0277.2009.01106.x
112. Myatt L., Role of placenta in preeclampsia. Endocrine 2002 19 1 103 111 2-s2.0-0036822281 10.1385/ENDO:19:1:103 (Pubitemid 36106256)
113. Liu A. X., He W. H., Yin L. J., Lv P. P., Zhang Y., Sheng J. Z., Leung P. C. K., Huang H. F., Sustained endoplasmic reticulum stress as a cofactor of oxidative stress in decidual cells from patients with early pregnancy loss. Journal of Clinical Endocrinology and Metabolism 2011 96 3 E493 E497 2-s2.0-79952303538 10.1210/jc.2010-2192
114. Lian I. A., Loset M., Mundal S. B., Increased endoplasmic reticulum stress in decidual tissue from pregnancies complicated by fetal growth restriction with and without pre-eclampsia. Placenta 2011 32 11 823 829
115. Vigod S. N., Seeman M. V., Ray J. G., Temporal trends in general and age-specific fertility rates among women with schizophrenia (19962009): apopulation-based study in Ontario, Canada. Schizophrenia Research. In press 10.1016/j.schres.2012.05.010
116. Ramkisson R., Campbell M., Agius M., The clinical dilemmaprescribing in pregnancy. Psychiatria Danubina 2008 20 1 88 90 2-s2.0-41949086616